Merck Manual

Please confirm that you are a health care professional

honeypot link

AstraZeneca Reports Slightly Lower Estimate of COVID-19 Vaccine Effectiveness

03/25/21 By
HealthDay News

THURSDAY, March 25, 2021 (HealthDay News) -- Following a sharp rebuke from an independent oversight board over potentially misleading information on the effectiveness of its COVID-19 vaccine, AstraZeneca released new data late Wednesday that showed the vaccine is slightly less effective than the company claimed on Monday.

The pharmaceutical giant stressed that its vaccine is still very powerful at preventing infection with COVID-19, based on more recent data than were used when the company first announced the interim results of its U.S. clinical trial.

After saying that the vaccine was 79 percent effective on Monday, the company said Wednesday that the vaccine was 76 percent effective at preventing COVID-19.

"The [latest] primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over," Mene Pangalos, Ph.D., executive vice president of BioPharmaceuticals R&D at AstraZeneca, said in a company news release. "We look forward to filing our regulatory submission for Emergency Use Authorization in the U.S. and preparing for the rollout of millions of doses across America."

AstraZeneca Press Release

Test your knowledge
Small Intestinal Bacterial Overgrowth (SIBO)
Small intestinal bacterial overgrowth can lead to vitamin deficiencies, fat malabsorption, and undernutrition. This syndrome can be caused by anatomic alterations or intestinal motility disorders. Which of the following may cause bacterial overgrowth in older people?